Jasper Therapeutics, Inc. — Form SCHEDULE 13D/A
Filed July 20, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 18/100
What the filing says
Velan Capital Investment Management LP filed an amended Schedule 13D/A on July 20, 2026, regarding its beneficial ownership stake in Jasper Therapeutics, Inc. The filing document itself contains no numerical details, share counts, ownership percentages, or transaction amounts—only administrative header information (addresses, CIKs, and filing metadata). The specific amendment details are not disclosed in the provided text.
Why this rating
Amendment to existing ownership disclosure; no material transaction, ownership change, or dollar amount specified in available text. Routine regulatory filing.
See more from July 20, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.